AnTolRx Closes Series A Funding Totalling $4M

AnTolRx, Inc., a Cambridge, Mass.-based developer of treatment of autoimmune diseases, closed a Series A funding agreement totalling $4m over two next two years.

The round was led by Pfizer (NYSE: PFE), with participation from Orion Equity Partners and JDRF.

The company intends to use the funds for research and development of its antigen-specific Targeted Nanoparticle Tolerance Therapeutics (TNTT) to treat immune disorders including T1D, which is┬ábased on the work of Dr. Francisco Quintana, Associate Scientist at Brigham and Women’s Hospital and Associate Professor of Neurology at Harvard Medical School.

AnTolRx is led by Mark Carthy, Chief Executive Officer.



Join the discussion